Mibefradil is a unique T- and L-type calcium channel antagonist with a pharmacokinetic profile supporting once-daily dosing for hypertension and angina.
May support once-daily T/L-type blockade in hypertension and angina; leaves open its clinical role pending randomized trials.
Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. This article will review pertinent results from in vitro, animal, and clinical investigations to report the pharmacologic properties that distinguish mibefradil from all of the calcium channel antagonists in use today, all of which operate on the "L-type" calcium channel. Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris.
No takes yet. Share an insight, caveat, or question.
A 1997 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: